Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model

Journal of Clinical Investigation

Volumn 118, Issue 7, 2008, Pages 2651-2660

  Bordeleau, Marie Eve ^a   Robert, Francis ^a   Gerard, Baudouin ^b   Lindqvist, Lisa ^a   Chen, Samuel M H ^a   Wendel, Hans Guido ^c   Brem, Brigitte ^d   Greger, Harald ^d   Lowe, Scott W ^e   Porco Jr , John A ^b   Pelletier, Jerry ^a,f  

^a MCGILL UNIVERSITY   (Canada)

^b Boston University   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 O FORMYLAGLAFOLINE; ANTINEOPLASTIC AGENT; BENZOFURAN DERIVATIVE; DEAD BOX PROTEIN; DOXORUBICIN; INITIATION FACTOR 4E; MESSENGER RNA; PHOSPHATASE; RAPAMYCIN; SILVESTROL; TENSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN FUNCTION; RIBOSOME; SCREENING; TRANSLATION INITIATION; TUMOR GROWTH;

EID: 46749097944     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JC134753     Document Type: Article

References (65)

1. Raught, B., Gingras, A.-C., and Sonenberg, N. 2000. Regulation of ribosome recruitment in eukaryotes. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 245-293.
2. Pestova, T.V., et al. 2001. Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl. Acad. Sci. U. S. A. 98:7029-7036.
3. Dorrello, N.V., et al. 2006. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 314:467-471.
4. Yang, H.S., et al. 2003. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol. Cell. Biol. 23:26-37.
5. Avdulov, S., et al. 2004. Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in humanmammary epithelial cells. Cancer Cell. 5:553-563.
6. Lazaris-Karatzas, A., Montine, K.S., and Sonenberg, N. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature. 345:544-547.
7. Fukuchi-Shimogori, T., et al. 1997. Malignant transformation by overproduction of translation initiation factor eIF4G. Cancer Res. 57:5041-5044.
8. Zhang, L., Pan, X., and Hershey, J.W. 2007. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J. Biol. Chem. 282:5790-5800.
9. Wendel, H.-G., et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332-337.
10. Wendel, H.G., et al. 2006. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 66:7639-7646.
11. Ruggero, D., et al. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484-486.
12. Polunovsky, V.A., et al. 1996. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc. Mol. Cell. Biol. 16:6573-6581.
13. Tan, A., Bitterman, P., Sonenberg, N., Peterson, M., and Polunovsky, V. 2000. Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1. Oncogene. 19:1437-1447.
14. Li, S., et al. 2003. Translation factor eIF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J. Biol. Chem. 278:3015-3022.
15. Grolleau, A., et al. 2002. Global and specific translational control by rapamycin in T cells uncovered by microarrays and proteomics. J. Biol. Chem. 277:22175-22184.
16. Rajasekhar, V.K., et al. 2003. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell. 12:889-901.
17. Mamane, Y., et al. 2007. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS ONE. 2:e242.
18. Rousseau, D., Gingras, A.C., Pause, A., and Sonenberg, N. 1996. The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene. 13:2415-2420.
19. De Benedetti, A., Joshi-Barve, S., Rinker-Schaeffer, C., and Rhoads, R.E. 1991. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol. Cell. Biol. 11:5435-5445.
20. Graff, J.R., et al. 2007. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J. Clin. Invest. 117:2638-2648.
21. Jansen, A.P., Camalier, C.E., and Colburn, N.H. 2005. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res. 65:6034-6041.
22. Hwang, B.Y., et al. 2004. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J. Org. Chem. 69:3350-3358.
23. Novac, O., Guenier, A.S., and Pelletier, J. 2004. Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen. Nucleic Acids Res. 32:902-915.
24. Hausott, B., Greger, H., and Marian, B. 2004. Flavaglines: a group of efficient growth inhibitors block cell cycle progression and induce apoptosis in colorectal cancer cells. Int. J. Cancer. 109:933-940.
25. Lee, S.K., Cui, B., Mehta, R.R., Kinghorn, A.D., and Pezzuto, J.M. 1998. Cytostatic mechanism and antitumor potential of novel 1H-cyclopenta-[b] benzofuran lignans isolated from Aglaia elliptica. Chem. Biol. Interact. 115:215-228.
26. Kim, S., et al. 2006. Cytotoxic flavaglines and bisamides from Aglaia edulis. J. Nat. Prod. 69:1769-1775.
27. Mi, Q., et al. 2006. Rocaglaol induces apoptosis and cell cycle arrest in LNCaP cells. Anticancer Res. 26:947-952.
28. Kim, S., Salim, A.A., Swanson, S.M., and Kinghorn, A.D. 2006. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med. Chem. 6:319-345.
29. Ohse, T., Ohba, S., Yamamoto, T., Koyano, T., and Umezawa, K. 1996. Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata. J. Nat. Prod. 59:650-652.
30. ++-dependent cross-linking of cap binding proteins to the 5′ end of eukaryotic mRNA. Nucleic Acids Res. 9:1643-1656.
31. Pause, A., Methot, N., Svitkin, Y., Merrick, W.C., and Sonenberg, N. 1994. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. EMBO J. 13:1205-1215.
32. Yoder-Hill, J., Pause, A., Sonenberg, N., and Merrick, W.C. 1993. The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A. J. Biol. Chem. 268:5566-5573.
33. Rocak, S., and Linder, P. 2004. DEAD-box proteins: the driving forces behind RNA metabolism. Nat. Rev. Mol. Cell Biol. 5:232-241.
34. Jurica, M.S., andMoore, M.J. 2003. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell. 12:5-14.
35. Holcik, M., Gibson, H., and Korneluk, R.G. 2001. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 6:253-261.
36. Polunovsky, V.A., et al. 2000. Translational control of the antiapoptotic function of Ras. J. Biol. Chem. 275:24776-24780.
37. Li, S., et al. 2002. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol. Cell Biol. 22:2853-2861.
38. Schneider, R.J., and Sonenberg, N. 2007. Translational control in cancer development and progression. In Translational control in biology and medicine. M.B. Mathews, N. Sonenberg, and J.W.B. Hershey, editors. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 934 pp.
39. Svitkin, Y.V., et al. 2001. The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA. 7:382-394.
40. Larsson, O., et al. 2006. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res. 34:4375-4386.
41. Bordeleau, M.E., et al. 2005. Stimulation of mammalian translation initiation factor eIF4A activity by a small molecule inhibitor of eukaryotic translation. Proc. Natl. Acad. Sci. U. S. A. 102:10460-10465.
42. Bordeleau, M.E., et al. 2006. RNA-mediated sequestration of the RNA helicase eIF4A by Pateamine A inhibits translation initiation. Chem. Biol. 13:1287-1295.
43. Mi, Q., et al. 2006. Silvestrol regulates G2/M check-point genes independent of p53 activity. Anticancer Res. 26:3349-3356.
44. Proksch, P., et al. 2005. Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells J. Immunol. 174:7075-7084.
45. Baumann, B., et al. 2002. Rocaglamide derivatives are potent inhibitors of NF-κB activation in T-cells. J. Biol. Chem. 277:44791- 44800.
46. Bordeleau, M.-E., et al. 2006. Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat. Chem. Biol. 2:213-220.
47. Wang, H., et al. 2002. Dendritic BC1 RNA: functional role in regulation of translation initiation. J. Neurosci. 22:10232-10241.
48. Wang, H., et al. 2005. Dendritic BC1 RNA in translational control mechanisms. J. Cell Biol. 171:811-821.
49. Eberle, J., Krasagakis, K., and Orfanos, C.E. 1997. Translation initiation factor eIF-4A1 mRNA is consistently overexpressed in human melanoma cells in vitro. Int. J. Cancer. 71:396-401.
50. Shuda, M., et al. 2000. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Res. 20:2489-2494.
51. Jansen, A.P., Camalier, C.E., Stark, C., and Colburn, N.H. 2004. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. Mol. Cancer Ther. 3:103-110.
52. Li, B.D., Liu, L., Dawson, M., and De Benedetti, A. 1997. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer. 79:2385-2390.
53. Rosenwald, I.B. 2004. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene. 23:3230-3247
54. Martin, M.E., et al. 2000. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int. J. Biochem. Cell Biol. 32:633-642.
55. Faivre, S., Kroemer, G., and Raymond, E. 2006. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5:671-688.
56. O'Reilly, K.E., et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
57. Zeng, Z., et al. 2007. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 109:3509-3512.
58. Sarbassov, D.D., et al. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/ PKB. Mol. Cell. 22:159-168.
59. Guertin, D.A., and Sabatini, D.M. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12:9-22.
60. Kim, S., et al. 2007. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 27:2175-2183.
61. Greger, H., Pacher, T., Brem, B., Bacher, M., and Hofer, O. 2001. Insecticidal flavaglines and other compounds from Fijian Aglaia species. Phytochemistry. 57:57-64.
62. Gerard, B., Sangji, S., O'Leary, D.J., and Porco, J.A., Jr. 2006. Enantioselective photocycloaddition mediated by chiral Bronsted acids: asymmetric synthesis of the rocaglamides. J. Am. Chem. Soc. 128:7754-7755.
63. Meurer-Grimes, B.M., Yu, J., and Vairo, G.L. 2004. Therapeutic compounds and methods. US Patent 6710075, 28, filed Nov. 8, 2002, and issued Mar. 23, 2004.
64. Edery, I., et al. 1983. Involvement of eukaryotic initiation factor 4A in the cap recognition process. J. Biol. Chem. 258:11398-11403.
65. Grollman, A.P. 1967. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J. Biol. Chem. 242:3226-3233.